Qiagen (NYSE:QGEN) Updates Q3 2026 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its third quarter 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.620- for the period, compared to the consensus earnings per share estimate of 0.630. The company issued revenue guidance of $538.3 million-$543.7 million, compared to the consensus revenue estimate of $552.7 million.

Qiagen Stock Down 0.6%

Shares of QGEN stock traded down $0.24 during trading on Thursday, reaching $41.71. The company’s stock had a trading volume of 4,028,165 shares, compared to its average volume of 2,442,216. Qiagen has a one year low of $32.53 and a one year high of $57.81. The business has a fifty day moving average price of $39.21 and a 200-day moving average price of $41.73. The company has a market cap of $8.59 billion, a price-to-earnings ratio of 21.78, a price-to-earnings-growth ratio of 4.22 and a beta of 0.63. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. The business had revenue of $535.00 million during the quarter, compared to the consensus estimate of $527.50 million. During the same quarter last year, the firm earned $0.60 earnings per share. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. Analysts anticipate that Qiagen will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The business also recently declared an annual dividend, which was paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th were given a dividend of $0.35 per share. This represents a yield of 90.0%. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date of this dividend was Tuesday, July 7th. Qiagen’s payout ratio is currently 18.32%.

Analysts Set New Price Targets

QGEN has been the subject of a number of analyst reports. Citigroup restated a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $43.00 price objective on shares of Qiagen in a research note on Thursday, April 30th. Robert W. Baird set a $43.00 price objective on Qiagen and gave the company an “outperform” rating in a report on Wednesday, April 29th. Kepler Capital Markets set a $38.60 target price on shares of Qiagen and gave the company a “hold” rating in a research note on Thursday, June 25th. Finally, Weiss Ratings cut shares of Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $42.43.

Qiagen News Summary

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen exceeded its second-quarter outlook, reporting $535 million in sales and adjusted diluted EPS of $0.62, compared with analyst estimates of $527.5 million and $0.60, respectively. Sales were roughly flat year over year but better than the company’s prior expectation for an approximately 2% constant-exchange-rate decline. QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
• Positive Sentiment: The company reaffirmed its full-year 2026 adjusted EPS outlook of approximately $2.43, in line with consensus, while maintaining solid profitability. Its growth pillars reportedly delivered 5% constant-exchange-rate growth, supporting the case for continued demand in key molecular diagnostics and life-sciences markets. Qiagen N.V. 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: Qiagen’s second-quarter net margin was 19.16%, and revenue increased approximately 0.2% year over year. However, the earnings beat was modest, with EPS declining from $0.63 a year earlier to $0.62, indicating limited earnings growth so far.
• Negative Sentiment: Qiagen guided third-quarter 2026 EPS to approximately $0.62, below the $0.63 consensus estimate, and revenue to $538.3 million-$543.7 million, below analysts’ $552.7 million forecast. The revenue shortfall is likely the key reason for the stock’s weaker performance, despite the second-quarter beat. Full-year revenue guidance of roughly $2.1 billion also remains below the approximately $2.2 billion consensus expectation.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Boston Partners acquired a new stake in Qiagen in the 3rd quarter worth about $179,450,000. Dimensional Fund Advisors LP bought a new stake in shares of Qiagen during the 3rd quarter valued at $58,079,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Qiagen by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after purchasing an additional 906,589 shares in the last quarter. Caisse de depot et placement du Quebec bought a new position in shares of Qiagen in the third quarter worth $27,082,000. Finally, Invesco Ltd. increased its position in shares of Qiagen by 123.7% in the second quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock worth $48,350,000 after purchasing an additional 556,387 shares during the period. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.